Hvad angår risikoen for samordnet praksis, finder Kommissionen, at denne risiko er minimal overvejende af samme årsager som for ikke-genetisk modificeret flydende lecitin (ingen prisgennemsigtighed, asymmetriske markedsandele m.v.)
As for the risk that the merger will elicit coordinated behaviour, the Commission considers that such a risk is negligible, mainly for the same reasons as for non-GM fluid lecithin (no price transparency, asymmetry of market shares etc.).